Brief-TSF.com

Education for Brief Twelve Step Facilitation of alcoholics and addicts

Archive for the 'Medication' Category


Substance Abuse and Mental Disorders

Posted by Lakeside on 9th June 2008

Man with co-occurring substance abuse and mental disorder The Co-Occurring Center for Excellence. Addressing mental disorders and alcoholism, addiction co-occurring.

The Co-Occurring Center for Excellence (COCE) was created by SAMHSA in 2003 to provide information and a range of services to mental health and substance abuse administrators and policymakers at state and local levels, their counterparts in tribal and Native populations, clinical providers, other providers, and all other agencies and systems through which clients may enter the treatment system.

COCE provides state-of-the-art and sustainable technical assistance, training, information and resources, and links to other resources that serve persons with co-occurring disorders.

http://www.coce.samhsa.gov/

See also;

          The Dual Diagnosis Recovery Sourcebook :
A Physical, Mental, and Spiritual Approach to Addiction with an Emotional Disorder

by Dennis Ortman

Read more about this title…


Subscribe to Brief-TSF.com by Email

Posted in Alcohol, Alcoholism, Contrast to other models, Drugs, Medication, Pharmacotherapy, Recovery, Relapse prevention, Symptoms of addiction, Target populations, Training | No Comments »

Antidepressant Induced Mania

Posted by Lakeside on 6th June 2008

angry manic man Antidepressant Induced Mania (ADM) Among People with Co-Occurring Disorders (COD). Sometimes, informally called Bipolar III disorder.

A recent study of medical charts at a bipolar specialty clinic gives new support to the idea that antidepressants can induce mania in some bipolar patients.

For some time, clinicians have been concerned about the problem of antidepressant-induced mania (ADM), but most research has not supported the connection between antidepressants and manic or hypomanic episodes.

This study looked at ADM and examined differences between patients with bipolar disorder and a substance use disorder (SUD) and patients without SUD.

The article presents solid evidence for a significantly increased risk of ADM in patients with co-occurring bipolar disorder and SUD. The article also comments about why the increased risk to these clients may not have been identified in prior research.

Manwani and colleagues investigated medical charts from 98 patients who were treated at a bipolar clinic between 2000 and 2004. These patients accounted for 335 antidepressant trials during that period. Of the sample, 55 patients (accounting for 184 of the trials) had a lifetime history of a SUD.

For this study, an episode of ADM was defined as hypomanic or manic symptoms within 12 weeks of beginning a new antidepressant medication.

There were some substantial differences between patients who did and did not have a SUD history—e.g., clients with SUD were almost twice as likely as those without SUD to be prescribed lithium (48.3% vs. 28.5%), and clients without SUD were twice as likely to receive divalproex as those with SUD (43% vs. 20.1%) and almost three times as likely to be prescribed an antipsychotic (31.8% vs. 11.4%).

The univariate analysis of differences in the number of antidepressant trials leading to ADM between patients with and without a SUD history showed little difference in the percentage of ADM episodes they experienced (20.7% of trials for those with SUD and 21.4% of trials for those without).

However, using a multivariate regression model of analysis, the authors found that:

  • Patients with a lifetime SUD were five times as likely to experience ADM,
  • The incidence of an antidepressant trial leading to an ADM was greater for clients with Type II or with bipolar disorder not otherwise specified than for Type I,
  • Females were more likely than males to have an episode of ADM in response to an antidepressant trial, and
  • Bupropion was the antidepressant least likely to cause an ADM.

The authors surmise that older research studies excluding people with a SUD might have led to subject pools that underrepresented individuals considerably more likely to experience an ADM than the subjects studied. Additionally, they describe how other confounding factors might have served to hide the effects of having a history of SUD on the likelihood of suffering an ADM.

A discussion of the limitations of their study (e.g., it was non-randomized, non-blind; concomitant therapy may have obscured treatment effect; no measures of adherence to medication regimens) is also given.

Research; Manwani, S. G., Pardo, T. B., Albanese, M. J., Zablotsky, B., Goodwin, F. K., & Ghaemi, S. N. (2006). Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. Journal of Clinical Psychiatry, 67(9), 1341–1345.

Co-Occurring Disorders Research and Resources Monthly Review. The Co-Occurring Center for Excellence (COCE), of the Substance Abuse and Mental Health Services Administration (SAMHSA), Vol. 1, No. 5, December 2006. Readers interested in finding out more about COCE should visit the Web site: http://coce.samhsa.gov/

See also;

          Dual Diagnosis,
Counseling the Mentally Ill Substance Abuser

by Katie Evans, J. Michael Sullivan

Read more about this title…


Subscribe to Brief-TSF.com by Email

Posted in Adjunctive therapy, Alcohol, Alcoholism, Assessment, Drugs, Medication, Pharmacotherapy, Recovery, Relapse prevention, Research, Target populations | No Comments »

25 Top Posts at BriefTSF

Posted by Lakeside on 1st June 2008

Popular Blogging at BriefTSF

          Understanding and Counselling the Alcoholic
by Jr. Howard J. Clinebell

Amazon books; Read more about this title…


Subscribe to Brief-TSF.com by Email

Posted in Addiction, Adult Children of Alcoholics, Alcohol, Alcoholics Anonymous, Alcoholism, Blogroll, Brief-TSF, Drugs, Higher Power, Inhalants, Medication, PTSD, Pharmacotherapy, Recovery, Relapse prevention, Research, Spirituality, Stages of Change, Symptoms of addiction, TSF, Target populations, Training, Women | No Comments »

Acamprosate for Alcohol Craving

Posted by Lakeside on 30th May 2008

Alcoholic Beverage Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials.

In 2004, the United States Food and Drug Administration (FDA) approved acamprosate for use in conjunction with psychosocial support in the maintenance of abstinence in alcohol-dependent patients who are abstinent at treatment initiation.

That approval was based primarily on a re-analysis of three European double-blind, placebo-controlled trials in which complete abstinence was the primary outcome measure.

The current report presents data from the re-analysis of the pivotal trials, which were 13-, 48-, and 52-week studies. A total of 998 DSM-III-R alcohol-dependent patients were included in the studies, with the majority abstinent at randomization. Using a more stringent definition of abstinence, re-analysis of the rate of complete abstinence, percent days abstinent, and the time to first drink confirmed the original findings for the efficacy of acamprosate in the treatment of alcohol dependence.

Rate of complete abstinence was significantly higher with acamprosate than placebo (p < .05); both percent days abstinent and time to first drink were also significantly greater among acamprosate-treated than placebo-treated patients (p < .01).

These findings support the use of acamprosate in the treatment of alcohol dependence and illustrate some of the issues that can arise in the FDA process for approval of medications to treat the disorder.

Am J Addict. 2008 Jan-Feb;17(1):70-6. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Kranzler HR, Gage A.

See also;

          Handbook of Alcoholism Treatment Approaches (3rd Edition)
by Reid K. Hester, William R. Miller

Read more about this title…


Subscribe to Brief-TSF.com by Email

Posted in Adjunctive therapy, Alcohol, Alcoholism, Medication, Pharmacotherapy, Relapse prevention, Research, Training | No Comments »

Popular Articles

Posted by Lakeside on 15th April 2008

Subscribe to BriefTSF by e-Mail


Subscribe to Brief-TSF.com by Email

Posted in 12-Step Groups, Addiction, Adult Children of Alcoholics, Al-anon, Alcohol, Alcoholics Anonymous, Alcoholism, Assessment, Brief-TSF, Co-dependency, Disease of addiction, Drugs, Family, Gambling, Higher Power, Medication, Men, Mutual-help, Pharmacotherapy, Recovery, Relapse prevention, Self-help, Spirituality, Symptoms of addiction, TSF, Women, Youth | No Comments »

E-mail Communication as an Adjunctive Tool in Addiction Medicine

Posted by Lakeside on 14th April 2008

Patient-Provider E-mail Communication as an Adjunctive Tool in Addiction Medicine

Frequent electronic mail communication between patients and their addiction specialist can be utilized as an adjunct in the treatment of alcohol or substance dependency.

Selected patients benefit from mandatory daily electronic mail communications with their provider through enhanced accountability, frequent self-assessment, deterrents to isolation, and a sense of continuous access to care. Participants have found the experience easy and enjoyable and all have maintained continuous sobriety.

We present our experience using this modality as a series of illustrative case reports and a discussion of the implications of using electronic mail with patients in addiction medicine.

Research report; Patient-Provider E-mail Communication as an Adjunctive Tool in Addiction Medicine. Gregory B. Collins, Mark S. McAllister, Donald B. Ford. Journal of Addictive Diseases, Volume: 26 Issue: 2

Subscribe to Brief-TSF.com by Email

Posted in Addiction, Adjunctive therapy, Alcohol, Alcoholism, Disease of addiction, Medication, Relapse prevention, Research, Target populations | No Comments »

Anti Craving Medication Works

Posted by Lakeside on 14th March 2008

j0178954

Extended-Release Naltrexone Works Particularly Well for Abstinent Patients with Dependence

Many patients with alcohol dependence do not receive the full benefits of treatment because they do not adhere to it. In part to address issues with adherence, extended-release (ER) naltrexone, which is released over a month after one injection, was developed. Pharmacotherapy researchers assessed ER-naltrexone efficacy in a subgroup of 82 subjects in a larger clinical trial who had ?4 days of abstinence.

In that subgroup, 380 mg of ER-naltrexone in 28 subjects versus placebo in 28 subjects

  • increased the time to first drink (median days, 41 versus 12);
  • increased continuous abstinence over 6 months (32% versus 11%);
  • increased time to first heavy drinking (>180 versus 20 days);
  • decreased days with any drinking (median days per month, 0.7 versus 7.2);
  • decreased days with heavy drinking (median days per month, 0.2 versus 2.9).

Smaller benefits, which were not always statistically significant, were found among 28 subjects treated with 190 mg of ER-naltrexone.

Comments by Michael Levy, PhD:
In this industry-sponsored secondary analysis of a small subgroup of subjects who had achieved just 4 or more days of abstinence before entering treatment, those who received ER-naltrexone in conjunction with psychosocial treatment had better treatment outcomes than those who received placebo. Medications with proven benefit for the treatment of alcohol dependence tend to be underutilized in general. This study suggests that ER-naltrexone is another treatment option for clients with alcohol dependence who have achieved even a short duration of abstinence.

Research Reference: O’Malley SS, Garbutt JC, Gastfriend DR, et al. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharm. 2007;27(5):507–512.

From; Join Together Online

Brief-TSF is designed to as adjunctive therapy for anti-craving medication.


Subscribe to Brief-TSF.com by Email

Posted in Adjunctive therapy, Alcohol, Alcoholism, Medication, Pharmacotherapy, Research, Stages of Change, Symptoms of addiction | No Comments »

Family history of alcoholism affects response to drug used to treat heavy drinking

Posted by Lakeside on 3rd March 2008

September 19, 2007 – Naltrexone is one of four oral medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholism.

A recent large multicenter research study of alcohol dependence supported by the National Institute of Alcoholism and Alcohol Abuse (NIAAA), the COMBINE Study, suggested that naltrexone produced a modest but significant benefit but another FDA-approved medication, acamprosate, was ineffective.

Perhaps consistent with its modest effects in COMBINE, naltrexone is not widely prescribed in the treatment of alcoholism. Yet, clinicians report that naltrexone may have significant benefits for individual patients.

To make naltrexone a more useful medication, it would be important to begin to identify groups of patients who might be more or less likely to show a significant clinical benefit from naltrexone prescription and to understand the causes of differential naltrexone efficacy. A new study that will appear in the September 15th issue of Biological Psychiatry suggests that alcohol dependent individuals with a family history of alcohol dependence may be more likely than alcohol dependent individuals without a family history of alcohol dependence to reduce their drinking in the laboratory when prescribed naltrexone.

Krishnan-Sarin and colleagues at the NIAAA Center for the Translational Neuroscience of Alcoholism studied alcohol consumption in the laboratory by alcohol-dependent individuals who were not seeking treatment.

The participants were studied in the laboratory after 6 days of treatment with 0 mg (placebo), 50 mg, or 100 mg of naltrexone. The authors discovered that naltrexone decreased drinking in those with a family history of alcoholism and this effect was greatest with the highest naltrexone dose.

However, it increased drinking in those without a family history of alcoholism and this effect was greatest at the highest naltrexone dose.

John H. Krystal, M.D., one of the authors, notes that “When studied in large groups, naltrexone appears to have a rather small effect upon the ability to reduce drinking or remain abstinent from alcohol.

However, there is growing evidence that there are subgroups of patients who show substantial benefit from naltrexone, even when naltrexone fails to work in the overall trial (see Gueorguieva R et al. Biol Psychiatry. 2007 Jun 1;61(11):1290-5).”

According to Suchitra Krishnan-Sarin, Ph.D., the lead author, “The results suggest that family history of alcoholism may be an important predictor of clinical response to naltrexone and could potentially be used to guide clinical practice.”

Dr. Krystal agrees, “These data suggest that family history might influence the optimal dosing of naltrexone and the nature of the clinical response.” Their hope is that these findings ultimately can contribute to a better treatment experience for some who are seeking to end their battle with alcohol.

Research articles; Suchitra Krishnan-Sarin, John H. Krystal, Julia Shi, Brian Pittman and Stephanie S. O’Malley. Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking” Biological Psychiatry, Volume 62, Issue 6.  and R. Gueorguieva, R. Wu, B. Pittman, J. Cramer, R.A. Rosenheck, S.S. O’Malley and J.H. Krystal. New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. Biol Psychiatry. 2007 Jun 1;61(11):1290-5.

Brief-TSF is designed as adjunctive therapy to complement anti-craving pharacotherapy.


Subscribe to Brief-TSF.com by Email

Posted in Adjunctive therapy, Alcohol, Alcoholism, Medication | No Comments »

Sleep problems affect alcoholism recovery

Posted by Lakeside on 14th February 2008

Sleep problems - real and perceived - get in the way of alcoholism recovery

Doctors and patients should discuss and address sleep issues as part of recovery

The first few months of recovery from an alcohol problem are hard enough. But they’re often made worse by serious sleep problems, caused by the loss of alcohol’s sedative effects, and the long-term sleep-disrupting impact that alcohol dependence can have on the brain.

Now, a new study gives further evidence that insomnia and other sleep woes may actually get in the way of recovery from alcohol problems. In fact, a person’s perception of how bad their sleep problems are may be just as important as the actual sleep problems themselves, the study suggests.

The study is published in the journal Alcoholism: Clinical and Experimental Research, by a team from the University of Michigan’s Department of Psychiatry. They report the results of a small but thorough evaluation of sleep, sleep perception and alcohol relapse among 18 men and women with insomnia who were in the early stages of alcohol recovery.

The authors say their results show how important it is for alcohol recovery patients, and those who are helping them through their recovery, to discuss sleep disturbances and seek help. Often, sleep isn’t discussed in alcohol recovery programs - but it should be, they stress.

In fact, members of the U-M team have now launched a new study that aims to help those who have just entered treatment for alcohol problems, and are having trouble sleeping. Instead of using sleep medications, which can carry their own risk of addiction, it’s based on a series of "talk therapy" sessions with a trained sleep therapist who can help patients change behaviors and patterns of thinking that contribute to sleep problems.

p_image001

Sleep and Half Brother Death [Drunk] by John William Waterhouse

In the meantime, the newly published results add to the understanding of how alcohol and sleep intertwine.

"What we found is that those patients who had the biggest differences between their perception of how they slept and their actual sleep patterns were most likely to relapse," says lead author Deirdre Conroy, Ph.D., who led the study as a fellow in the U-M Addiction Research Center. "This suggests that long-term drinking causes something to happen in the brain that interferes with both sleep and perception of sleep. If sleep problems aren’t addressed, the risk of relapse may be high."

"We are now interested in what brain mechanisms are involved in the disrupted sleep of alcohol-dependent individuals," says Brower, who has previously led studies illustrating the prevalence of sleep disorders among people with alcohol dependence and abuse issues, and their correlation with relapse back into drinking. He is the executive director of the U-M Addiction Treatment Services, which provides alcohol and drug treatment to hundreds of patients each year.

The new study involved women who had volunteered for a randomized clinical trial of gabapentin, an experimental treatment for alcohol dependence. Each one started the trial when they had been off alcohol for about a week.

The volunteers spent two separate nights in the sleep-monitoring area of the U-M General Clinical Research Center, wearing electrodes on their head and body that measured their brain waves during sleep, as well as their breathing, muscle activity and heart rhythm. The detailed measurements, which together make up a procedure called polysomnography, allowed the researchers to determine when the volunteers were sleeping, when they were awake, and which stage of sleep they were in.

These sleep data were compared with the participants’ answers on morning evaluations of how they slept - including how long they thought it took them to fall asleep, how long they were awake in the night, and other measures. The two nights of sleep monitoring were done several weeks apart. The researchers also asked the participants to report any alcohol they drank during the six weeks following each sleep test.

In all, the patients overestimated how long it took them to fall asleep, but thought they had been awake in the middle of the night for far less time than they actually were. These perceptions about how they slept were actually more accurate in predicting their potential for relapse to alcohol use than were the actual sleep measurements.

"Our study suggests that in early recovery from alcoholism, people perceived that it took them a long time to fall asleep and that they slept through the night," says Conroy. "The reality was that it did not take them as long to fall asleep as they thought it did, and their brain was awake for a large portion of the night. On average, the participants that were less accurate about how they were sleeping were more likely to return to drinking."

Conroy explains that poor sleep quality can lead to mood disturbances. "If recovering alcoholics are irritable because they are not getting quality sleep at night, they might be more vulnerable to return to drinking," she says. "Previous studies show that non-alcoholics with insomnia actually think they are sleeping worse than they are, so they may be more likely to seek appropriate treatment.

Our study shows that an alcoholic in early recovery has a lot of wakefulness in the night but they are not necessarily picking up on this. It is important for the clinician working with the alcohol-dependent patient to have a differential of poor sleep quality in the back of their mind as a potential challenge for the patient throughout alcohol recovery."

Kara Gavin | Source: EurekAlert! Further information: www.umich.edu


The Insomnia Solution: The Natural, Drug-Free Way to a Good Night’s Sleep


Subscribe to Brief-TSF.com by Email

Posted in Adjunctive therapy, Alcohol, Alcoholism, Assessment, Drugs, Medication, Relapse prevention, Research, Stages of Change | No Comments »

Heath Ledger’s Death Seen as Caution on Prescription Drugs

Posted by Lakeside on 12th February 2008

 

Heath Ledger Heath Ledger’s father and others are casting the death of the young actor as a warning about the dangers of prescription drug use.

Reacting to the New York medical examiner’s ruling that Ledger, 28, died of an accidental overdose of multiple painkillers and sedatives, the actor’s father, Kim Ledger, said, “While no medications were taken in excess, we learned today the combination of doctor-prescribed drugs proved lethal for our boy. Heath’s accidental death serves as a caution to the hidden dangers of combining prescription medication, even at low dosage.”

The elder Ledger’s comments were reported by the Associated Press on Feb. 7. Ledger died in his New York hotel room on Jan. 22.

Meanwhile, the U.S. Drug Enforcement Administration is looking into how Ledger acquired such a large quantity of prescription drugs, the Boston Herald reported Feb. 7. “We are working with the NYPD to identify any illegally prescribed drugs that may have been prescribed to Ledger,” said DEA spokesman Erin Mulvey.

Toxicology reports found that Ledger died from “acute intoxication by the combined effects of oxycodone, hydrocodone, diazepam, temazepam, alprazolam and doxylamine.”

See also;

Prescription Drug Overdose Becomes Big Killer

Taking Oxycodone / Oxycontin Safely


Subscribe to Brief-TSF.com by Email

Posted in Drugs, Medication | No Comments »